Brief Summary
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Protocol Interventions
Drug: INCB123667
Advanced Physician Search: Platinum Resistant
202212039
Brief Summary
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
Protocol Interventions
Drug: Azenosertib, Biological: Bevacizumab